StockData

Biofrontera vs Journey Medical

BFRI and DERM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BFRI and DERM compare

Journey Medical is the larger company, worth 12 times as much as Biofrontera ($104M against $8.5M).

Journey Medical grew revenue faster over the last twelve months (20.9% versus 17.8% for Biofrontera).

Journey Medical keeps more of each dollar of sales as profit, with a net margin of −9.0% compared with −13.8% at Biofrontera.

Biofrontera scores higher on the StockData Score (10 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBFRIDERM
Size and price
Market cap$8.5M$104M
Share price$0.570$3.70
Change, 1 year−36.0%−51.9%
Change, 5 years−99.6%−56.4%
Beta (5Y)1.962.01
Employees9258
StockData Score
Total score10 (better)7
Valuation score12 (better)
Growth score2 (better)1
Performance score23 (better)
Health score5 (better)1
Dividend score00
Valuation
P/S0.2× (better)1.5×
P/B1.4× (better)3.3×
FCF yield−93.7%–
Fair value–$5.98
Margin of safety–38.1%
Growth
Revenue growth (TTM)17.8%20.9% (better)
Revenue growth, 5Y average17.2% (better)6.8%
Profitability
Gross margin–65.5%
Operating margin−14.2%−4.4% (better)
Net margin−13.8%−9.0% (better)
FCF margin−17.2%–
Return on equity−988%−23.8% (better)
Return on invested capital–−8.5%
Financial health
Debt / equity0.000.79 (better)
Interest coverage–−0.8×
Current ratio1.181.59 (better)
Altman Z-score−6.360.43 (better)
Piotroski F-score35 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions18.6%37.8%
Held by insiders23.6%15.3%
Short interest, % of float1.7%12.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.